Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
PURPOSE - - Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2022]
|
| In: |
Journal of clinical oncology
Year: 2022, Jahrgang: 40, Heft: 29, Pages: 3365-3376 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.22.01002 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.22.01002 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.22.01002 
|
| Verfasserangaben: | Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, and Sara M. Tolaney, on behalf of the TROPiCS-02 study investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 183291531X | ||
| 003 | DE-627 | ||
| 005 | 20230706234933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230201s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.01002 |2 doi | |
| 035 | |a (DE-627)183291531X | ||
| 035 | |a (DE-599)KXP183291531X | ||
| 035 | |a (OCoLC)1389535924 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rugo, Hope S. |e VerfasserIn |0 (DE-588)1020214171 |0 (DE-627)691143218 |0 (DE-576)359869203 |4 aut | |
| 245 | 1 | 0 | |a Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer |c Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, and Sara M. Tolaney, on behalf of the TROPiCS-02 study investigators |
| 264 | 1 | |c [2022] | |
| 300 | |b Diagramme | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.02.2023 | ||
| 520 | |a PURPOSE - - Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer. - - METHODS - - In this global, randomized, phase III study, SG was compared with physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2- locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review. - - RESULTS - - Patients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83; P = .0003]). The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively. Median overall survival (first planned interim analysis) was not yet mature (hazard ratio, 0.84; P = .14). Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%). - - CONCLUSION - - SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options. | ||
| 700 | 1 | |a Bardia, Aditya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Cortes, Javier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loirat, Delphine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trédan, Olivier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ciruelos, Eva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dalenc, Florence |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pardo, Patricia Gómez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jhaveri, Komal L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delaney, Rosemary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fu, Olivia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lin, Lanjia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verret, Wendy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolaney, Sara M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 40(2022), 29, Seite 3365-3376 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:29 |g pages:3365-3376 |g extent:12 |a Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.22.01002 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.22.01002 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230201 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 50000 |d 60000 |d 61300 |e 50000PM132561972 |e 60000PM132561972 |e 61300PM132561972 |k 0/50000/ |k 0/60000/ |k 1/60000/61300/ |p 3 | ||
| 999 | |a KXP-PPN183291531X |e 4261385902 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Hope S.","role":"aut","display":"Rugo, Hope S.","family":"Rugo"},{"given":"Aditya","role":"aut","family":"Bardia","display":"Bardia, Aditya"},{"display":"Marmé, Frederik","family":"Marmé","given":"Frederik","role":"aut"},{"family":"Cortes","display":"Cortes, Javier","given":"Javier","role":"aut"},{"given":"Peter","role":"aut","display":"Schmid, Peter","family":"Schmid"},{"family":"Loirat","display":"Loirat, Delphine","role":"aut","given":"Delphine"},{"family":"Trédan","display":"Trédan, Olivier","role":"aut","given":"Olivier"},{"display":"Ciruelos, Eva","family":"Ciruelos","role":"aut","given":"Eva"},{"role":"aut","given":"Florence","family":"Dalenc","display":"Dalenc, Florence"},{"given":"Patricia Gómez","role":"aut","family":"Pardo","display":"Pardo, Patricia Gómez"},{"given":"Komal L.","role":"aut","display":"Jhaveri, Komal L.","family":"Jhaveri"},{"family":"Delaney","display":"Delaney, Rosemary","role":"aut","given":"Rosemary"},{"role":"aut","given":"Olivia","family":"Fu","display":"Fu, Olivia"},{"family":"Lin","display":"Lin, Lanjia","given":"Lanjia","role":"aut"},{"role":"aut","given":"Wendy","family":"Verret","display":"Verret, Wendy"},{"family":"Tolaney","display":"Tolaney, Sara M.","given":"Sara M.","role":"aut"}],"language":["eng"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"[2022]"}],"note":["Gesehen am 01.02.2023"],"title":[{"title_sort":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","title":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, and Sara M. Tolaney, on behalf of the TROPiCS-02 study investigators"]},"physDesc":[{"noteIll":"Diagramme","extent":"12 S."}],"recId":"183291531X","relHost":[{"title":[{"title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"pubHistory":["1.1983 -"],"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerJournal of clinical oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"313116962","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"language":["eng"],"part":{"volume":"40","extent":"12","text":"40(2022), 29, Seite 3365-3376","issue":"29","pages":"3365-3376","year":"2022"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}]}],"id":{"eki":["183291531X"],"doi":["10.1200/JCO.22.01002"]}} | ||
| SRT | |a RUGOHOPESBSACITUZUMA2022 | ||